CompletedNot Applicable

Genotype Information and Functional Testing Study

United States2,000 participantsStarted 2009-10-01

Plain-language summary

This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients meeting inclusion criteria for GRAVITAS who undergo VerifyNow blood sampling for VerifyNow P2Y12 platelet function testing and IVRS entry for GRAVITAS randomization/selection determination Exclusion Criteria: * See GRAVITAS trial (ClinicalTrials.gov identifier: NCT00645918)

What they're measuring

residual platelet reactivity

Timeframe: 6 months

Trial details

NCT IDNCT00992420

SponsorScripps Health

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2010-08-31

View on ClinicalTrials.gov More Coronary Artery Disease trials